Social Media Listening for Routine Post-Marketing Safety Surveillance

Gregory E. Powell (), Harry A. Seifert, Tjark Reblin, Phil J. Burstein, James Blowers, J. Alan Menius, Jeffery L. Painter, Michele Thomas, Carrie E. Pierce, Harold W. Rodriguez, John S. Brownstein, Clark C. Freifeld, Heidi G. Bell and Nabarun Dasgupta
Additional contact information
Gregory E. Powell: GlaxoSmithKline
Harry A. Seifert: GlaxoSmithKline Vaccines
Tjark Reblin: GlaxoSmithKline
Phil J. Burstein: GlaxoSmithKline
James Blowers: GlaxoSmithKline
J. Alan Menius: GlaxoSmithKline
Jeffery L. Painter: GlaxoSmithKline
Michele Thomas: Blue Zone Industries
Carrie E. Pierce: Epidemico Inc.
Harold W. Rodriguez: Epidemico Inc.
John S. Brownstein: Epidemico Inc.
Clark C. Freifeld: Epidemico Inc.
Heidi G. Bell: Zero Chaos
Nabarun Dasgupta: Epidemico Inc.

Drug Safety, 2016, vol. 39, issue 5, No 8, 443-454

Abstract: Abstract Introduction Post-marketing safety surveillance primarily relies on data from spontaneous adverse event reports, medical literature, and observational databases. Limitations of these data sources include potential under-reporting, lack of geographic diversity, and time lag between event occurrence and discovery. There is growing interest in exploring the use of social media (‘social listening’) to supplement established approaches for pharmacovigilance. Although social listening is commonly used for commercial purposes, there are only anecdotal reports of its use in pharmacovigilance. Health information posted online by patients is often publicly available, representing an untapped source of post-marketing safety data that could supplement data from existing sources. Objectives The objective of this paper is to describe one methodology that could help unlock the potential of social media for safety surveillance. Methods A third-party vendor acquired 24 months of publicly available Facebook and Twitter data, then processed the data by standardizing drug names and vernacular symptoms, removing duplicates and noise, masking personally identifiable information, and adding supplemental data to facilitate the review process. The resulting dataset was analyzed for safety and benefit information. Results In Twitter, a total of 6,441,679 Medical Dictionary for Regulatory Activities (MedDRA®) Preferred Terms (PTs) representing 702 individual PTs were discussed in the same post as a drug compared with 15,650,108 total PTs representing 946 individual PTs in Facebook. Further analysis revealed that 26 % of posts also contained benefit information. Conclusion Social media listening is an important tool to augment post-marketing safety surveillance. Much work remains to determine best practices for using this rapidly evolving data source.

Date: 2016
References: View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
http://link.springer.com/10.1007/s40264-015-0385-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:39:y:2016:i:5:d:10.1007_s40264-015-0385-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-015-0385-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().